The AML‐MRC entity was redefined by the WHO 20163 classification on the basis of molecular markers, and the presence of multilineage dysplasia alone thus did no longer classify a case as AML‐MRC if a good prognosis NPM1 or biallelic CEBPA mutation was present.3 Here, CEBPA is linked to acute myeloid leukemia.